Enzene Upstream Process Development (UPD) team has extensive experience in the development, characterization, and scale-up of a wide range of therapeutic proteins. These include recombinant monoclonal antibodies, antibody fragments, and fusion proteins based on microbial and mammalian platforms. We are committed to developing continuous bioprocesses for mammalian cell-based products using perfusion technology.
We use the latest equipment in our facility to achieve the high degree of accuracy and quality needed, supported by world-class infrastructures, such as